Comparison of the acyl chain specificities of human myristoyl-CoA synthetase and human myristoyl-CoA:protein N-myristoyltransferase.
Human myristoyl-CoA synthetase and myristoyl-CoA:protein N-myristoyltransferase (hNmt) have been partially purified from an erythroleukemia cell line. Their substrate specificities were examined using two in vitro assays of enzyme activity together with a panel of C7-C17 saturated fatty acids plus 72 myristic acid analogs containing oxygen, sulfur, ketocarbonyl, ester, amide, cis and trans double bonds, triple bonds, and para-substituted phenyl groups. There is an inverse relationship between the polarity and the activity of C14 fatty acid substrates of myristoyl-CoA synthetase. Surveys of tetradecenoic and tetradecynoic acids suggest that myristate is bound to the synthetase in a bent conformation with a principal bend occurring in the vicinity of C5-C6. The synthetase can tolerate a somewhat wider range of physical chemical properties in acyl chains than can the monomeric hNmt. However, like myristoyl-CoA synthetase, there is an inverse relationship between acyl chain polarity and the activities of hNmt's acyl-CoA substrates. Moreover, the acyl chain of myristoyl-CoA appears to be bound to hNmt in a bent conformation with bends located in the vicinity of C5 and C8. The acyl chain specificities of both enzymes make them well suited to utilize efficiently any cellular pools of 5Z-tetradecenoic and 5Z,8Z-tetradecadienoic acids and their CoA derivatives. This feature may account for the recent observation that in some mammalian cell lineages, certain N-myristoyl-proteins are heterogeneously acylated with these C14 fatty acids. Finally, the acyl-CoA binding sites of human and Saccharomyces cerevisiae Nmts appear to have been highly conserved. Given their overlapping yet distinct peptide substrate specificities, development of species-specific inhibitors of Nmts should probably focus on structural features recognized in the enzymes' peptide substrates rather than in the acyl chain of their acyl-CoA substrates.
Kishore
N S
NS
Department of Infectious Diseases, G. D. Searle Co., St. Louis, Missouri.
Wood
D C
DC
Mehta
P P
PP
Wade
A C
AC
Lu
T
T
Gokel
G W
GW
Gordon
J I
JI
D000214:Acyl Coenzyme A / Q000378:metabolism; D000217:Acyltransferases / Q000378:metabolism*; D003066:Coenzyme A Ligases / Q000737:chemistry / Q000378:metabolism*; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D007535:Isomerases / Q000378:metabolism; D004915:Leukemia, Erythroblastic, Acute; D019814:Myristic Acid; D009227:Myristic Acids / Q000737:chemistry / Q000378:metabolism; D011487:Protein Conformation; D011549:Pseudomonas / Q000201:enzymology; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured
D000214:Acyl Coenzyme A; D005227:Fatty Acids; D009227:Myristic Acids; D019814:Myristic Acid; D000217:Acyltransferases; C050480:glycylpeptide N-tetradecanoyltransferase; D007535:Isomerases; D003066:Coenzyme A Ligases; C079990:myristoyl-CoA synthetase